NCT07357051: Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd. Phase: PHASE3. Conditions: Respiratory Viral Infection